Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Liver Injury due to Intravenous Methylprednisolone in the Drug-Induced Liver Injury Network.
Liver Int
February 2025
Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland, USA.
Background And Aims: Short courses of intravenous (iv) methylprednisolone (MP) can cause drug induced liver injury (DILI). The aim of this study was to assess the clinical features and HLA associations of MP-related DILI enrolled in the US DILI Network (DILIN).
Methods: DILIN cases with MP as a suspected drug were reviewed.
Dexamethasone synergizes with high-fat diet to increase lipid deposition in adipocytes.
Korean J Intern Med
January 2025
Department of Basic Nutrition, Ningbo College of Health Sciences, Ningbo, China.
Background/aims: Dexamethasone (DEX) is a widely used exogenous therapeutic glucocorticoid in clinical settings. Its long-term use leads to many side effects. However, its effect on metabolic disorders in individuals on a high-fat diet (HFD) remains poorly understood.
View Article and Find Full Text PDFHealthy Lifestyle Changes Improve Cortisol Levels and Liver Steatosis in MASLD Patients: Results from a Randomized Clinical Trial.
Nutrients
December 2024
Scientific Direction, National Institute of Gastroenterology IRCCS "Saverio de Bellis", 70013 Castellana Grotte, BA, Italy.
Article Synopsis
- Steatotic liver disease linked to metabolic dysfunction (MASLD) is prevalent in up to 30% of adults and is often associated with obesity and metabolic syndrome.
- The study involved 42 patients split into three groups receiving different treatments: dietary advice only (CG), dietary advice plus aerobic exercise (AE + DA), and dietary advice plus high-intensity interval training (HIIT + DA).
- Results showed that both exercise groups had significant reductions in cortisol levels, with HIIT + DA showing the greatest effects, and a notable decrease in hepatic steatosis was also observed, particularly in the AE + DA group.
Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis.
Aliment Pharmacol Ther
February 2025
Department of Medicine, Division of Gastroenterology and Hepatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA.
Background: EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO-101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).
Aims: To evaluate the efficacy, safety and tolerability of ESO-101 in patients with active EoE.
Survival Benefit From Corticosteroids in Severe Alcohol-associated Hepatitis Attributed to Clinical and Treatment Differences in a Large Multicenter Cohort.
Clin Transl Gastroenterol
January 2025
Department of Medicine, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Introduction: Corticosteroids are recommended by multiple society guidelines for the treatment of severe alcohol-associated hepatitis (AH). However, their use remains controversial due to inconsistent studies regarding their survival benefit.
Methods: This was a retrospective cohort study of first-time hospitalizations for severe AH (Maddrey discriminant function ≥ 32) admitted to the Veterans Health Administration between January 3, 2005, and December 5, 2020, (i) evaluating the effect of corticosteroid therapy on all-cause survival, (ii) characterizing the clinical and psychosocial factors associated with corticosteroid use, and (iii) determining the effect of duration of corticosteroid therapy on all-cause survival among treatment-responsive patients (Lille score < 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!